Amundi Asset Management US’s Haemonetics HAE Stock Holding History

Amundi Asset Management US’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$4.68M	Buy	42,174 +4,941	+13%	+$611K	﹤0.01%	1025
2020 Q4	$4.42M	Buy	37,233 +4,729	+15%	+$509K	﹤0.01%	999
2020 Q3	$2.83M	Buy	32,504 +6,861	+27%	+$600K	﹤0.01%	1023
2020 Q2	$2.3M	Buy	25,643 +2,084	+9%	+$211K	﹤0.01%	1042
2020 Q1	$2.35M	Sell	23,559 -10,238	-30%	-$1.11M	﹤0.01%	918
2019 Q4	$3.88M	Buy	33,797 +9,298	+38%	+$1.13M	﹤0.01%	975
2019 Q3	$3.09M	Buy	+24,499	New	+$3.11M	﹤0.01%	999
2019 Q2	–	Sell	-7,391	Closed	-$647K	–	1678
2019 Q1	$647K	Hold	7,391	–	–	﹤0.01%	1286
2018 Q4	$739	Buy	7,391 +5,466	+284%	+$574K	﹤0.01%	1211
2018 Q3	$221K	Buy	+1,925	New	+$199K	﹤0.01%	1449

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's HAE Position: Q1 2021 in Review

Amundi Asset Management US increased its Haemonetics (HAE) stake by 13% in Q1 2021, buying an estimated $611K and bringing the position to 42,174 shares worth $4.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1025.

Amundi Asset Management US first reported a position in HAE in Q3 2018 and has held it in 10 quarters since. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

Amundi Asset Management US held 42,174 shares of Haemonetics worth $4.68M as of Q1 2021.
Amundi Asset Management US bought 4,941 Haemonetics shares in Q1 2021, an estimated $611K.
Haemonetics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1025 holding.
Amundi Asset Management US first reported a position in Haemonetics in Q3 2018 and has held it in 10 quarters since.
296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.